Back to Search
Start Over
Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy
- Source :
- Stalman , E W , Wieske , L , Keijser , J B D , the T2B! Immunity against SARS-CoV-2 study group , van Dam , K P J , Kummer , L Y L , Wilbrink , M F , van Kempen , Z L E , Killestein , J , Volkers , A G , Tas , S W , Boekel , L , Wolbink , G J , van der Kooi , A J , Raaphorst , J , Löwenberg , M , Takkenberg , R B , D'Haens , G R A M , Spuls , P I , Bekkenk , M W , Musters , A H , Post , N F , Bosma , A L , Hilhorst , M L , Vegting , Y , Bemelman , F J , Voskuyl , A E , Broens , B , Parra Sanchez , A , van Els , C A C M , de Wit , J , Rutgers , A , de Leeuw , K , Horváth , B , Verschuuren , J J G M , Ruiter , A M , van Ouwerkerk , L , van der Woude , D , Allaart , R C F , Onno Teng , Y K , van Paassen , P , Busch , M H , Brusse , E , van Doorn , P A , Baars , A E , Hijnen , D , Schreurs , C R G , van der Pol , W L , Goedee , H S , Cristianawati , O & Jonges , M 2024 , ' Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy ' , Journal of Allergy and Clinical Immunology , vol. 154 , no. 3 , pp. 754-766.e7 .
- Publication Year :
- 2024
-
Abstract
- Background: Despite impaired humoral response in patients treated with immunosuppressants (ISPs), recent studies found similar severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection compared to controls. One potential explanation is the rapid generation of humoral response on infection, but evidence is lacking. Objectives: We investigated the longitudinal dynamics of the SARS-CoV-2 antibody repertoire after SARS-CoV-2 delta and omicron breakthrough infection in patients with immune-mediated inflammatory diseases (IMIDs) receiving ISP therapy and controls. Methods: As a prospective substudy of the national Target-to-B! (T2B!) consortium, we included IMID patients receiving ISPs therapy and controls who reported SARS-CoV-2 breakthrough infection between July 1, 2021, and April 1, 2022. To get an impression of the dynamics of the antibody repertoire, 3 antibody titers of wild-type RBD, wild-type S, and omicron RBD were measured at 4 time points after SARS-CoV-2 breakthrough infection. Results: We included 302 IMID patients receiving ISPs and 178 controls. Antibody titers increased up to 28 days after breakthrough infection in both groups. However, in IMID patients receiving therapy with anti-CD20 and sphingosine-1 phosphate receptor modulators, antibody titers were considerably lower compared to controls. In the anti-TNF group, we observed slightly lower antibody titers in the early stages and a faster decline of antibodies after infection compared to controls. Breakthrough infections were mostly mild, and hospitalization was required in less than 1% of cases. Conclusions: Most ISPs do not influence the dynamics of the SARS-CoV-2 antibody repertoire and exhibit a rapid recall response with cross-reactive antibody clones toward new virus variants. However, in patients treated with anti-CD20 therapy or sphingosine-1 phosphate receptor modulators, the dynamics were greatly impaired, and to a lesser extent in those who received a
Details
- Database :
- OAIster
- Journal :
- Stalman , E W , Wieske , L , Keijser , J B D , the T2B! Immunity against SARS-CoV-2 study group , van Dam , K P J , Kummer , L Y L , Wilbrink , M F , van Kempen , Z L E , Killestein , J , Volkers , A G , Tas , S W , Boekel , L , Wolbink , G J , van der Kooi , A J , Raaphorst , J , Löwenberg , M , Takkenberg , R B , D'Haens , G R A M , Spuls , P I , Bekkenk , M W , Musters , A H , Post , N F , Bosma , A L , Hilhorst , M L , Vegting , Y , Bemelman , F J , Voskuyl , A E , Broens , B , Parra Sanchez , A , van Els , C A C M , de Wit , J , Rutgers , A , de Leeuw , K , Horváth , B , Verschuuren , J J G M , Ruiter , A M , van Ouwerkerk , L , van der Woude , D , Allaart , R C F , Onno Teng , Y K , van Paassen , P , Busch , M H , Brusse , E , van Doorn , P A , Baars , A E , Hijnen , D , Schreurs , C R G , van der Pol , W L , Goedee , H S , Cristianawati , O & Jonges , M 2024 , ' Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy ' , Journal of Allergy and Clinical Immunology , vol. 154 , no. 3 , pp. 754-766.e7 .
- Notes :
- application/pdf, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1456741637
- Document Type :
- Electronic Resource